乌司奴单抗对TNFi初治活动性银屑病关节炎伴医生报告脊柱炎患者脊柱炎相关终点的影响:两项3期随机对照试验汇总结果
基于PSUMMIT-1和PSUMMIT-2两项3期随机对照试验的汇总数据,评估乌司奴单抗在TNFi初治、伴医生报告脊柱炎的活动性银屑病关节炎患者中对脊柱炎相关终点的影响。共223例患者纳入分析,乌司奴单抗组第24周BASDAI颈/背/髋疼痛和mBASDAI改善均大于安慰剂组,ASDAS临床重要改善比例更高(49.6% vs 12.7%,名义p<0.05)。
要点
- 乌司奴单抗改善TNFi初治PsA伴脊柱炎患者的颈/背/髋疼痛和mBASDAI,第24周变化优于安慰剂。
- ASDAS临床重要改善(下降≥1.1)比例乌司奴单抗组49.6%,安慰剂组12.7%(名义p<0.05)。
- HLA-B27阳性患者颈/背/髋疼痛和疲劳改善数值上大于HLA-B27阴性患者。
核心结论
- 乌司奴单抗治疗TNFi初治、伴医生报告脊柱炎的PsA患者,BASDAI颈/背/髋疼痛和mBASDAI改善具有临床意义且各评估工具一致。
研究设计与样本
- PSUMMIT-1和PSUMMIT-2两项3期随机对照试验的汇总分析,纳入TNFi初治、活动性PsA伴医生报告脊柱炎患者223例(其中158例有HLA-B27结果)。
- 患者接受皮下乌司奴单抗45 mg、90 mg或安慰剂(第0、4、16周),评估第12和24周BASDAI颈/背/髋疼痛问题(#2)、mBASDAI和ASDAS应答。
主要发现
- 第24周BASDAI颈/背/髋疼痛平均变化乌司奴单抗组为-1.99,安慰剂组为-0.18;mBASDAI平均变化分别为-2.09和-0.59。
- 第24周ASDAS临床重要改善(下降≥1.1)比例乌司奴单抗组49.6%,安慰剂组12.7%(名义p<0.05)。
- HLA-B27阳性患者颈/背/髋疼痛和疲劳改善数值上大于HLA-B27阴性患者,其他领域改善一般一致。
关键数值与推荐
- 活动性PsA定义:≥5个肿胀关节和≥5个压痛关节,C反应蛋白≥3.0 mg/L。
- ASDAS临床重要改善定义为下降≥1.1。
- 基线疾病活动度:平均BASDAI颈/背/髋疼痛6.51,mBASDAI 6.54,BASDAI 6.51,ASDAS 3.81。
临床怎么用
- 对于TNFi初治、伴医生报告脊柱炎的活动性PsA患者,乌司奴单抗可改善脊柱炎相关症状如颈/背/髋疼痛和疾病活动度。
- HLA-B27阳性患者可能从乌司奴单抗获得更大的疼痛改善,但需结合整体疾病活动评估。
局限性
- 本文为两项试验的汇总分析,脊柱炎相关终点为次要分析,部分比较为名义p值。
- HLA-B27亚组分析为探索性,样本量有限(158例有结果)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The interleukin-12/23p40-subunit-inhibitor ustekinumab significantly improved spondylitis-related symptoms through Week 24 in psoriatic arthritis (PsA) patients with peripheral arthritis and physician-reported spondylitis (PA-PRS) in PSUMMIT-1&2. We further evaluated ustekinumab's effect on spondylitis-related endpoints in PSUMMIT-1&2 tumour necrosis factor-inhibitor (TNFi)-naïve patients with PA-PRS. METHODS: Patients with active PsA (≥5 swollen and ≥5 tender joints, C-reactive-protein ≥ 3.0 mg/L) despite conventional (PSUMMIT-1&2) and/or prior TNFi (PSUMMIT-2) therapy received subcutaneous ustekinumab 45 mg, 90 mg or placebo (Week 0, Week 4, Week 16). Changes in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) neck/back/hip pain question (#2) and modified BASDAI (mBASDAI, excluding PA) scores and Ankylosing Spondylitis Disease Activity Score (ASDAS) responses were assessed at Weeks 12 and 24. RESULTS: The pooled PSUMMIT-1&2, TNFi-naïve (n=747), PA-PRS (n=223) subset (158 with human-leucocyte-antigen (HLA)-B27 results) presented with moderate-to-severe spondylitis-related symptoms (mean BASDAI-neck/back/hip pain-6.51, mBASDAI-6.54, BASDAI-6.51, ASDAS-3.81). Mean Week 24 changes were larger among ustekinumab than placebo-treated patients for both neck/back/hip pain (-1.99 vs -0.18) and mBASDAI (-2.09 vs -0.59). Improvements in neck/back/hip pain and fatigue appeared numerically greater in HLA-B27+ than HLA-B27 - patients; those for other domains were generally consistent. Greater proportions of ustekinumab versus placebo-treated patients achieved ASDAS clinically important improvement at Week 24 (decrease ≥ 1.1; 49.6% vs 12.7%; nominal p<0.05). CONCLUSIONS: Improvements in BASDAI neck/back/hip pain and mBASDAI among ustekinumab-treated, TNFi-naïve, PsA patients with PA-PRS were clinically meaningful and consistent across assessment tools. Numerically greater improvements in neck/back/hip pain in HLA-B27+ than HLA-B27 - patients, noted in the context of similar overall mBASDAI improvements between the subgroups, suggest ustekinumab may improve disease activity in TNFi-naïve PsA patients likely to exhibit axial disease. CLINICAL TRIAL REGISTRATION NUMBERS: PSUMMIT 1, NCT01009086; PSUMMIT 2, NCT01077362.
引用
- Helliwell PS, Gladman DD, Chakravarty SD, et al. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. RMD Open. 2020. PMID: 32209721. doi:10.1136/rmdopen-2019-001149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。